SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic evaluations of personalized medicine: existing challenges and current developments
16 references·1 citing·43 second hop
Economic evaluations of personalized medicine: existing challenges and current developments (2015)Economic evaluations of personalized medi…The economic value of personalized medicine tests: what we know and what we need to know (2013)The economic value of persona…Issues Surrounding the Health Economic Evaluation of Genomic Technologies (2013)Issues Surrounding the Health…Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic …CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT (2013)CONSOLIDATED HEALTH ECONOMIC …The microeconomics of personalized medicine: today's challenge and tomorrow's promise (2009)The microeconomics of persona…Does Comparative-Effectiveness Research Threaten Personalized Medicine? (2009)Does Comparative-Effectivenes…The use of economic evaluations in NHS decision-making: a review and empirical investigation (2008)The use of economic evaluatio…Exploring Uncertainty in Cost-Effectiveness Analysis (2008)Exploring Uncertainty in Cost…Using Value of Information Analysis to Prioritise Health Research (2006)Using Value of Information An…Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment (2006)Good Practice Guidelines for …Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence? (2005)Establishing the Cost-Effecti…HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)HER-2 Testing and Trastuzumab…A systematic review of cost-effectiveness analyses of pharmacogenomic interventions (2004)A systematic review of cost-e…10.1016/b978-0-323-67762-2.50051-3 (2000)10.1016/b978-0-323-67762-2.50…The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment (1997)The Iterative Use of Economic…Estimating the costs of genomic sequencing in cancer control (2020)Estimating the costs of genom…Information Value Theory (1966)Statistical Decision Theory (1989)The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)Recent Developments in Decision-Analytic Modelling for Economic Evaluation (2006)Value based pricing for NHS drugs: an opportunity not to be missed? (2008)Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force (2020)Cost-Effectiveness in Health and Medicine (1996)Guidelines for authors and peer reviewers of economic submissions to the BMJ (1996)CONCEPTUALIZATIONS OF THE SOCIETAL PERSPECTIVE WITHIN ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW (2017)National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison (2021)Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (2021)Handling Uncertainty in Cost-Effectiveness Models (2000)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Conceptualizing a Model (2012)Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7 (2012)AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users (2015)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (2007)Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer (2007)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force (2022)Net Health Benefits (1998)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Uncertain Judgements: Eliciting Experts' Probabilities (2006)Accounting for Methodological, Structural, and Parameter Uncertainty in Decision-Analytic Models (2011)Cost-effectiveness analyses of genetic and genomic diagnostic tests (2018)Calculating and Interpreting ICERs and Net Benefit (2020)Clinical Decision Analysis (1980)Uncertainty in the economic evaluation of health care technologies: The role of sensitivity analysis (1994)'Early warning systems' for identifying new healthcare technologies. (1999)Clinical decision analysis (2005)Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature (2017)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)Prioritizing Comparative-Effectiveness Research — IOM Recommendations (2009)Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers (2010)Personality-informed interventions for healthy aging: Conclusions from a National Institute on Aging work group. (2013)S pectra O ptia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial (2014)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 2013Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement1,776 cited
  • 200010.1016/b978-0-323-67762-2.50051-31,156 cited
  • 2013CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT573 cited
  • 2006Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment504 cited
  • 2006Using Value of Information Analysis to Prioritise Health Research279 cited
  • 2009Does Comparative-Effectiveness Research Threaten Personalized Medicine?231 cited
  • 2004HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis230 cited
  • 2008Exploring Uncertainty in Cost-Effectiveness Analysis210 cited
  • 1997The Iterative Use of Economic Evaluation as Part of the Process of Health Technology Assessment208 cited
  • 2009The microeconomics of personalized medicine: today's challenge and tomorrow's promise166 cited
  • 2008The use of economic evaluations in NHS decision-making: a review and empirical investigation130 cited
  • 2005Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?121 cited
  • 2013The economic value of personalized medicine tests: what we know and what we need to know

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

119 cited
  • 2013Issues Surrounding the Health Economic Evaluation of Genomic Technologies108 cited
  • 2004A systematic review of cost-effectiveness analyses of pharmacogenomic interventions95 cited
  • Cited by

    • 2020Estimating the costs of genomic sequencing in cancer control52 cited